Food and Drug Administration

Gastrointestinal Drugs Advisory Committee

April 23, 2002

Slides

Lotronex^® (alosetron hydrochloride) Tablets, Dr. James Palmer, MD  pdf

GlaxoSmithKline  pdf

 Lotronex^® (alosetron HCI) Tablets Introduction, Dr. Victor Raczkowski, MD, FDA  htm  ppt

Lotronex: Clinical Trials, Thomas Permutt, FDA  htm  ppt

Lotronex Postmarketing Experience, Ann Corken Mackey, MPH, FDA  htm  ppt

Lotronex^® (alosetron HCI) Tablets Risk-Benefit Issues, Dr. Victor Raczkowski, MD, FDA  htm  ppt

Goals of a Lotronex^® Risk Management Program, Dr. Toni Piazza-Hepp, PharmD, FDA  htm ppt